AstraZeneca

Explore the latest insights on AstraZeneca and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of AstraZeneca’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
Explore the latest insights on AstraZeneca and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of AstraZeneca's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings
CompanyDrug

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer Inc. (NYSE: PFE) announced that ritlecitinib (brand name Litfulo), an oral kinase inhibitor, met the primary endpoints in two Phase III trials in nonsegmental vitiligo, with data presented at…

Qyuns Therapeutics' Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Dato-DXd Misses Overall Survival Endpoint but Shows Promise in NSCLC Subgroup

CompanyLegal / IP

AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs

Company

AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management

CompanyDeals

AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million

Company

AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion

CompanyDrug

AstraZeneca’s Strensiq Approved for Rare Disease Therapy under Greater Bay Area’s Drug Access Policy

CompanyDrug

AstraZeneca’s Strensiq Gains Approval for Rare Disease Therapy in Guangdong Under “Hong Kong-Macau Drug and Device Access”

CompanyDrug

AstraZeneca’s Fasenra Secures NMPA Approval for Severe Eosinophilic Asthma Maintenance Therapy

Show More